Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design.

The Protein Data Bank. Nucleic Acids Res (2000) 187.10

Surfing the p53 network. Nature (2000) 35.36

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42

Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26

Regulation of p53 stability by Mdm2. Nature (1997) 18.20

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53

Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48

Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12

Helix geometry in proteins. J Mol Biol (1988) 4.66

Convergent solutions to binding at a protein-protein interface. Science (2000) 4.47

Synthetic therapeutic peptides: science and market. Drug Discov Today (2009) 2.95

Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov (2014) 2.88

Implications of protein flexibility for drug discovery. Nat Rev Drug Discov (2003) 2.83

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc (2007) 2.71

Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A (2013) 2.22

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets (2005) 1.83

An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Eng (1999) 1.63

Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput Biol (2009) 1.61

Binding site detection and druggability index from first principles. J Med Chem (2009) 1.49

Computational approaches to identifying and characterizing protein binding sites for ligand design. J Mol Recognit (2010) 1.40

Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc (2011) 1.30

Design and structure of stapled peptides binding to estrogen receptors. J Am Chem Soc (2011) 1.22

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun (2013) 1.21

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem (2014) 1.21

Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. J Chem Theory Comput (2012) 1.18

Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc (2008) 1.16

Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol (2012) 1.14

Entropy-enthalpy transduction caused by conformational shifts can obscure the forces driving protein-ligand binding. Proc Natl Acad Sci U S A (2012) 1.12

Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics. Curr Opin Chem Biol (2011) 1.08

What induces pocket openings on protein surface patches involved in protein-protein interactions? J Comput Aided Mol Des (2008) 0.97

Modulating protein-protein interactions: the potential of peptides. Chem Commun (Camb) (2015) 0.96

Balancing target flexibility and target denaturation in computational fragment-based inhibitor discovery. J Comput Chem (2012) 0.96

Using ligand-mapping simulations to design a ligand selectively targeting a cryptic surface pocket of polo-like kinase 1. Angew Chem Int Ed Engl (2012) 0.94

Helix kinks are equally prevalent in soluble and membrane proteins. Proteins (2014) 0.87

Improving protocols for protein mapping through proper comparison to crystallography data. J Chem Inf Model (2013) 0.86

Active site pressurization: a new tool for structure-guided drug design and other studies of protein flexibility. J Chem Inf Model (2008) 0.84

The Application of Ligand-Mapping Molecular Dynamics Simulations to the Rational Design of Peptidic Modulators of Protein-Protein Interactions. J Chem Theory Comput (2015) 0.83

Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry. Proteomics (2013) 0.80

Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2. PLoS One (2014) 0.80

All-hydrocarbon stapled peptides as Synthetic Cell-Accessible Mini-Proteins. Drug Discov Today Technol (2012) 0.80

The use of chlorobenzene as a probe molecule in molecular dynamics simulations. J Chem Inf Model (2014) 0.79

Iminoguanidines as Allosteric Inhibitors of the Iron-Regulated Heme Oxygenase (HemO) of Pseudomonas aeruginosa. J Med Chem (2016) 0.79

Stapled peptide design: principles and roles of computation. Drug Discov Today (2016) 0.78

Computational functional group mapping for drug discovery. Drug Discov Today (2016) 0.75